Core Insights - Earth Science Tech, Inc. (ETST) has qualified for and been listed on the newly launched OTCID tier of the OTC Markets, reflecting its commitment to enhanced disclosure and compliance standards [1][2] - The CEO, Giorgio R. Saumat, highlighted the company's significant turnaround over the past two years and expressed optimism about future growth and increased investor confidence due to this new designation [3] Company Overview - ETST operates as a strategic holding company focused on acquiring and optimizing high-potential businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through various subsidiaries [4] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each specializing in different aspects of healthcare and real estate [4][10] Subsidiary Highlights - **RxCompoundStore.com**: A fully licensed compounding pharmacy serving multiple states and actively pursuing licensure in remaining U.S. states [5] - **Mister Meds**: A compounding pharmacy in Texas that received full licensure in March 2025 and is expanding its service area [6] - **Peaks Curative**: A telemedicine platform offering consultations for compounded medications and recently expanded into the veterinary market [7] - **Las Villas Health Care**: A healthcare facility focused on the Spanish-speaking community, providing specialized health services [8] - **Avenvi**: A diversified real estate company managing development and financing activities, overseeing a $5 million share repurchase program [10] - **Earth Science Foundation**: A nonprofit organization supporting individuals with financial needs for prescription costs [11]

Core Viewpoint - A new Florida law effective July 1, 2025, allows physicians to provide investigational stem cell therapies for orthopedics, wound care, and pain management, with strict safety and ethical standards in place [1][2]. Group 1: New Legislation - The law permits the use of stem cell therapies not yet approved by the FDA, with strict limits on the sources of stem cells, which must come from FDA-registered facilities [2][4]. - Physicians are required to obtain informed consent from patients before administering these therapies [2]. Group 2: Company Positioning - Celularity Inc. is prepared to supply ethically sourced stem cells for these treatments and has a facility that complies with the new law's requirements [2][4]. - The company has extensive knowledge and real-world data from clinical trials related to the therapies authorized under the new law [3][4]. Group 3: Industry Impact - The Florida Medical Association was involved in crafting the legislation to balance public protection against ineffective therapies and avoid overregulation of physicians [4]. - The law is seen as a potential model for other states, emphasizing the role of physicians in assessing the best therapeutic approaches for patients [4]. Group 4: Company Overview - Celularity Inc. specializes in regenerative and cellular medicine, focusing on placental-derived cell therapies and advanced biomaterial products [5]. - The company aims to address significant unmet global needs for effective and affordable therapies by utilizing the unique biology of the placenta [5].

Core Viewpoint - The expansion of AIC equity investment pilot business in Shenzhen has led to the establishment of three AIC funds with a total scale of 5 billion yuan, indicating a significant increase in investment activity in key industries such as technology and innovation [1][2][3]. Group 1: Fund Establishment and Scale - Three AIC funds have been registered in Shenzhen, with a combined scale of 50 billion yuan [1]. - The Shenzhen Deep Investment Control Qianfan Qihang Science and Technology Private Equity Investment Fund has a scale of 2 billion yuan and focuses on over 30 projects in key industries like semiconductors and artificial intelligence [2]. - The Shenzhen Guangming Zhongying Fuyao Science and Technology Private Equity Investment Fund has a scale of 1 billion yuan, targeting the "3+3+1" industrial system in the Guangming District [2]. - The Shenzhen Deep Investment Control Gongrong Science and Technology Private Equity Investment Fund also has a scale of 2 billion yuan, focusing on strategic emerging industries [3]. Group 2: Collaboration Models - The primary collaboration model for the new funds is "municipal and district state-owned enterprises + banking AIC," which aims to support the development of hard technology sectors [4]. - Deep Investment Control, a state-owned capital operation platform, is a partner in two of the funds, with a total fund scale exceeding 150 billion yuan [5]. Group 3: Broader AIC Developments - The AIC equity investment pilot program has expanded from Shanghai to 18 cities, leading to a surge in fund establishment and investment projects [5]. - Major banks, including Agricultural Bank of China and Bank of China, have established AICs, with a total intended cooperation scale of 30 billion yuan in Tianjin and 17.5 billion yuan in Ningbo [6]. - In 2024, AIC investment activity reached a historical peak, with 156 investment cases totaling 57.6 billion yuan [6]. Group 4: Impact on Technology Innovation - The role of AIC in supporting technological innovation is expected to become increasingly significant, leveraging the advantages of state-owned commercial banks in various aspects [7].

低调但关键的城市定位 无锡的特殊在于 ： 其4627平方公里的面积在长三角核心城市中最小，比苏州小近一倍。其"壮士断腕"最为猛烈（关停数千家污染企业）、其产业传承和承接上海相关技术溢 出颇为巧妙，最终"用六十分的牌打出九十分"—— ●无锡人均GDP连续第四年超越上海。 ●在土地面积远小于苏州、杭州等城市的情况下，工业用地的产出效率在长三角、乃至全国都是领先水平。同时精准嵌入国家战略齿轮——成为集成电路 等高附加值产业的核心布局节点。 江南"小"城，不追逐灼目的聚光灯，却在长三角的创新拼图中，以不可或缺的姿态托举起整片星群的光辉。 作为先行者，无锡的"小城大业"对其他城市也颇有借鉴意义—— 找准自身特色与国家战略的结合点。 北京，清华大学的实验室。屏幕上是复杂的气动模型，工程师调整参数，敲下回车键。数据流开始奔涌。在经历了无数次计算模拟后，国产大飞机与天宫 一号终于正式踏上征服苍穹之路。 承载这些数据洪流的核心算力——在千里之外一座江南小城，一个不起眼的灰色建筑中。 source：unsplash无锡 长三角的夜空群星璀璨。 以龙头上海为原点向外延伸，依次是苏州的外资制造集群、杭州的数字经济生态、南京的产学研转 ...

NFL super-agent Leigh Steinberg opens up about the brain trauma crisis in football and his mission to protect athletes through advocacy, research, and a groundbreaking collaboration on stem cell therapy. Learn more: https://european-wellness.eu/ The man who inspired the multiple award-winning movie “Jerry Maguire” meets the pioneering stem cell scientist who is transforming regenerative medicine. Together, they may just hold the key to healing the silent epidemic of sports-related brain injuries. A ...

Group 1 - The core point of the article is that Tongrentang Medical Investment Co., Ltd. has submitted its third listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor. If successful, it will become the fourth listed platform under the Tongrentang Group [1] Group 2 - Tongrentang Medical is a traditional Chinese medicine healthcare group providing comprehensive medical services to individual clients and standardized management services to institutional clients, along with various pharmaceutical and other products [5] - As of the latest feasible date, Tongrentang Medical has established a tiered medical service network, including 12 self-owned offline medical institutions and one internet hospital, as well as 10 offline managed medical institutions [5] - By 2024, Tongrentang Medical is the largest non-public traditional Chinese medicine hospital group in China, holding a market share of 1.7% in terms of total outpatient and inpatient visits [5] - In terms of total medical service revenue for 2024, Tongrentang Medical accounts for 46.5% of the total market size of the traditional Chinese medicine healthcare service industry in China [5] - The company's revenue primarily comes from medical services, management services, and sales of health products and other products, with medical services generating approximately 995 million yuan, management services about 9.6 million yuan, and health product sales around 138 million yuan for the fiscal year 2023 [5] - The company's revenue for the fiscal years 2022, 2023, and 2024 was approximately 911 million yuan, 1.153 billion yuan, and 1.175 billion yuan respectively, with net profits of -9.233 million yuan, 42.634 million yuan, and 46.197 million yuan during the same periods [5]

Mustafa Suleyman is the CEO of Microsoft AI and co-founder of DeepMind. Suleyman joins Big Technology to discuss Microsoft’s new multi-agent “diagnostic orchestrator,” a system that debates patient cases and outperforms physicians on tough New England Journal of Medicine scenarios. Tune in to hear how this system already hits about 85 percent accuracy while slashing unnecessary tests and cost. We also cover what the rise of generative AI in medicine means for doctors’ roles, patient trust, real-world deploy ...

RT Seth Tigchelaar, MD/PhD (@sstigchelaar)I am excited to announce that we @umiamimedicine and @MiamiProject, have successfully implanted our first patient, RJ, as part of @neuralink's PRIME Study!Thank you @elonmusk for revolutionizing therapies for our patients! https://t.co/ES4VULbVG6 ...

Core Insights - Tempus AI (TEM) is experiencing significant growth in its Data and Services segment, with a 43.2% year-over-year revenue increase to $61.9 million in Q1 2025, driven by a 58% growth in its Insights data licensing business [1][7] - The company has secured major contracts, including a $200 million licensing agreement with AstraZeneca (AZN) and Pathos, which has increased AZN's total remaining contract value to over $1 billion [2][7] - Tempus has expanded collaborations with key pharmaceutical companies, including Illumina and Boehringer Ingelheim, enhancing its position in biomarker development and oncology applications [3][7] Financial Performance - Gross profit for Tempus outpaced revenue growth, increasing by 65.2% with only a modest 3% rise in the cost of revenues [1] - Year-to-date, Tempus AI shares have surged 102.5%, significantly outperforming the industry average growth of 18% [6] Competitive Landscape - Competitors like ICON (ICLR) and IQVIA (IQV) are also experiencing growth, but Tempus AI's performance in securing contracts and expanding its service offerings positions it favorably in the market [4][5] - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 8.47X, compared to the industry average of 5.83X, indicating a premium valuation [8]

Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses, today shares its financial results for the year ended March 31, 2025. For the fiscal year ended March 31, 2025, the Company reported the following results: Cash: $1,473,228, compared to $697,721 as of March 31, 2024—an increase of $775,507, representing a 1 ...